# A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM

> **NCT04967690** · PHASE1 · UNKNOWN · sponsor: **Double Bond Pharmaceutical AB** · enrollment: 27 (estimated)

## Conditions studied

- Newly Diagnosed Glioblastoma

## Interventions

- **DRUG:** SI-053

## Key facts

- **NCT ID:** NCT04967690
- **Lead sponsor:** Double Bond Pharmaceutical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01
- **Primary completion:** 2025-07
- **Final completion:** 2025-12
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04967690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04967690, "A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04967690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*